Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: An analysis of four different protease inhibitors

Paul M. Coplan, Alexander Nikas, Anthony Japour, Karen Cormier, Hilal D Maradit Kremers, Ron Lewis, Yi Xu, Mark J. DiNubile

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Protease inhibitor (PI) therapy for patients infected with the human immunodeficiency virus has been associated with lipid disorders and insulin resistance. We compared the incidence of myocardial infarction (MI) among participants receiving treatment with PIs with or without nucleoside reverse transcriptase inhibitors (nRTIs) to nRTI therapy alone in 30 phase II/III double-blind, randomized studies conducted before 1999 for the first 4 PI drugs. In most trials included in this analysis, participants could receive combination therapy with a PI plus nRTIs in open-label extensions after the blinded phase concluded. Person-years (PY) of follow-up were calculated from treatment initiation to the diagnosis of MI, or to the end of the randomized phases for nRTI-only therapy or to the conclusion of the studies for PI-containing regimens. Separate analyses were conducted for the randomized and the randomized-plus-extension phases. Among 10,986 participants, 7951 (72%) received PI drugs at some point for an average duration of 12 months. There were 10 MIs (1.31/1000 PY) in the randomized phases and 19 MIs (1.63/1000 PY) in the randomized-plus-extension phases. The overall stratified relative risk of MI for PI-containing (1.82 MI/1000 PY) versus nRTI-only (1.05 MI/1000 PY) regimens of 1.69 was not significantly increased (95% confidence interval [CI], 0.54 to 7.48). The absolute difference in MI risk was +0.77 (95% CI, -0.71 to +2.26) MIs/1000 PY. Compared with NRTI-only therapy, patients receiving PI-containing regimens for an average of 1 year did not have significantly more MIs, but the upper bound of the 95% CI indicates there may be up to 2.3 additional MIs per 1000 PY. Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Protease Inhibitors
Randomized Controlled Trials
Myocardial Infarction
Reverse Transcriptase Inhibitors
Incidence
Nucleosides
Therapeutics
Confidence Intervals
Double-Blind Method
Pharmaceutical Preparations
Insulin Resistance
HIV
Lipids

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy : An analysis of four different protease inhibitors. / Coplan, Paul M.; Nikas, Alexander; Japour, Anthony; Cormier, Karen; Maradit Kremers, Hilal D; Lewis, Ron; Xu, Yi; DiNubile, Mark J.

In: AIDS Research and Human Retroviruses, Vol. 19, No. 6, 01.06.2003, p. 449-455.

Research output: Contribution to journalArticle

Coplan, Paul M. ; Nikas, Alexander ; Japour, Anthony ; Cormier, Karen ; Maradit Kremers, Hilal D ; Lewis, Ron ; Xu, Yi ; DiNubile, Mark J. / Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy : An analysis of four different protease inhibitors. In: AIDS Research and Human Retroviruses. 2003 ; Vol. 19, No. 6. pp. 449-455.
@article{0bd094c319134960983d1a4f65ea9192,
title = "Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: An analysis of four different protease inhibitors",
abstract = "Protease inhibitor (PI) therapy for patients infected with the human immunodeficiency virus has been associated with lipid disorders and insulin resistance. We compared the incidence of myocardial infarction (MI) among participants receiving treatment with PIs with or without nucleoside reverse transcriptase inhibitors (nRTIs) to nRTI therapy alone in 30 phase II/III double-blind, randomized studies conducted before 1999 for the first 4 PI drugs. In most trials included in this analysis, participants could receive combination therapy with a PI plus nRTIs in open-label extensions after the blinded phase concluded. Person-years (PY) of follow-up were calculated from treatment initiation to the diagnosis of MI, or to the end of the randomized phases for nRTI-only therapy or to the conclusion of the studies for PI-containing regimens. Separate analyses were conducted for the randomized and the randomized-plus-extension phases. Among 10,986 participants, 7951 (72{\%}) received PI drugs at some point for an average duration of 12 months. There were 10 MIs (1.31/1000 PY) in the randomized phases and 19 MIs (1.63/1000 PY) in the randomized-plus-extension phases. The overall stratified relative risk of MI for PI-containing (1.82 MI/1000 PY) versus nRTI-only (1.05 MI/1000 PY) regimens of 1.69 was not significantly increased (95{\%} confidence interval [CI], 0.54 to 7.48). The absolute difference in MI risk was +0.77 (95{\%} CI, -0.71 to +2.26) MIs/1000 PY. Compared with NRTI-only therapy, patients receiving PI-containing regimens for an average of 1 year did not have significantly more MIs, but the upper bound of the 95{\%} CI indicates there may be up to 2.3 additional MIs per 1000 PY. Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy.",
author = "Coplan, {Paul M.} and Alexander Nikas and Anthony Japour and Karen Cormier and {Maradit Kremers}, {Hilal D} and Ron Lewis and Yi Xu and DiNubile, {Mark J.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1089/088922203766774487",
language = "English (US)",
volume = "19",
pages = "449--455",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy

T2 - An analysis of four different protease inhibitors

AU - Coplan, Paul M.

AU - Nikas, Alexander

AU - Japour, Anthony

AU - Cormier, Karen

AU - Maradit Kremers, Hilal D

AU - Lewis, Ron

AU - Xu, Yi

AU - DiNubile, Mark J.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Protease inhibitor (PI) therapy for patients infected with the human immunodeficiency virus has been associated with lipid disorders and insulin resistance. We compared the incidence of myocardial infarction (MI) among participants receiving treatment with PIs with or without nucleoside reverse transcriptase inhibitors (nRTIs) to nRTI therapy alone in 30 phase II/III double-blind, randomized studies conducted before 1999 for the first 4 PI drugs. In most trials included in this analysis, participants could receive combination therapy with a PI plus nRTIs in open-label extensions after the blinded phase concluded. Person-years (PY) of follow-up were calculated from treatment initiation to the diagnosis of MI, or to the end of the randomized phases for nRTI-only therapy or to the conclusion of the studies for PI-containing regimens. Separate analyses were conducted for the randomized and the randomized-plus-extension phases. Among 10,986 participants, 7951 (72%) received PI drugs at some point for an average duration of 12 months. There were 10 MIs (1.31/1000 PY) in the randomized phases and 19 MIs (1.63/1000 PY) in the randomized-plus-extension phases. The overall stratified relative risk of MI for PI-containing (1.82 MI/1000 PY) versus nRTI-only (1.05 MI/1000 PY) regimens of 1.69 was not significantly increased (95% confidence interval [CI], 0.54 to 7.48). The absolute difference in MI risk was +0.77 (95% CI, -0.71 to +2.26) MIs/1000 PY. Compared with NRTI-only therapy, patients receiving PI-containing regimens for an average of 1 year did not have significantly more MIs, but the upper bound of the 95% CI indicates there may be up to 2.3 additional MIs per 1000 PY. Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy.

AB - Protease inhibitor (PI) therapy for patients infected with the human immunodeficiency virus has been associated with lipid disorders and insulin resistance. We compared the incidence of myocardial infarction (MI) among participants receiving treatment with PIs with or without nucleoside reverse transcriptase inhibitors (nRTIs) to nRTI therapy alone in 30 phase II/III double-blind, randomized studies conducted before 1999 for the first 4 PI drugs. In most trials included in this analysis, participants could receive combination therapy with a PI plus nRTIs in open-label extensions after the blinded phase concluded. Person-years (PY) of follow-up were calculated from treatment initiation to the diagnosis of MI, or to the end of the randomized phases for nRTI-only therapy or to the conclusion of the studies for PI-containing regimens. Separate analyses were conducted for the randomized and the randomized-plus-extension phases. Among 10,986 participants, 7951 (72%) received PI drugs at some point for an average duration of 12 months. There were 10 MIs (1.31/1000 PY) in the randomized phases and 19 MIs (1.63/1000 PY) in the randomized-plus-extension phases. The overall stratified relative risk of MI for PI-containing (1.82 MI/1000 PY) versus nRTI-only (1.05 MI/1000 PY) regimens of 1.69 was not significantly increased (95% confidence interval [CI], 0.54 to 7.48). The absolute difference in MI risk was +0.77 (95% CI, -0.71 to +2.26) MIs/1000 PY. Compared with NRTI-only therapy, patients receiving PI-containing regimens for an average of 1 year did not have significantly more MIs, but the upper bound of the 95% CI indicates there may be up to 2.3 additional MIs per 1000 PY. Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037714994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037714994&partnerID=8YFLogxK

U2 - 10.1089/088922203766774487

DO - 10.1089/088922203766774487

M3 - Article

C2 - 12882653

AN - SCOPUS:0037714994

VL - 19

SP - 449

EP - 455

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 6

ER -